<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ascelia Pharma Ab — News on 6ix</title>
<link>https://6ix.com/company/ascelia-pharma-ab</link>
<description>Latest news and press releases for Ascelia Pharma Ab on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 30 Mar 2026 14:45:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ascelia-pharma-ab" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d561a4beedb30cb6f7f581.webp</url>
<title>Ascelia Pharma Ab</title>
<link>https://6ix.com/company/ascelia-pharma-ab</link>
</image>
<item>
<title>Notice of Annual General Meeting in Ascelia Pharma AB</title>
<link>https://6ix.com/company/ascelia-pharma-ab/news/notice-of-annual-general-meeting-in-ascelia-pharma-ab-1</link>
<guid isPermaLink="true">https://6ix.com/company/ascelia-pharma-ab/news/notice-of-annual-general-meeting-in-ascelia-pharma-ab-1</guid>
<pubDate>Mon, 30 Mar 2026 14:45:00 GMT</pubDate>
<description>The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. MALMÖ, SE / ACCESS Newswire / March 30, 2026 / Ascelia Pharma (STO:ACE) - The shareholders ...</description>
</item>
<item>
<title>Ascelia Pharma Announces Acceptance of Orviglance Data for Oral Presentation at the Annual Radiology Congress ESGAR 2026</title>
<link>https://6ix.com/company/ascelia-pharma-ab/news/ascelia-pharma-announces-acceptance-of-orviglance-data-for-oral-presentation-at-the-annual-radiology-congress-esgar-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/ascelia-pharma-ab/news/ascelia-pharma-announces-acceptance-of-orviglance-data-for-oral-presentation-at-the-annual-radiology-congress-esgar-2026-1</guid>
<pubDate>Fri, 27 Mar 2026 13:35:00 GMT</pubDate>
<description>MALMÖ, SE / ACCESS Newswire / March 27, 2026 / Ascelia Pharma (STO:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that an abstract with an evaluation of the detection of focal liver lesions ...</description>
</item>
<item>
<title>Ascelia Pharma Announces Deputy CEO Julie Waras Brogren to Leave the Company</title>
<link>https://6ix.com/company/ascelia-pharma-ab/news/ascelia-pharma-announces-deputy-ceo-julie-waras-brogren-to-leave-the-company-1</link>
<guid isPermaLink="true">https://6ix.com/company/ascelia-pharma-ab/news/ascelia-pharma-announces-deputy-ceo-julie-waras-brogren-to-leave-the-company-1</guid>
<pubDate>Wed, 21 Jan 2026 10:00:00 GMT</pubDate>
<description>MALMÖ, SE / ACCESS Newswire / January 21, 2026 / Ascelia Pharma AB (publ) (STO:ACE) today announced that Deputy CEO Julie Waras Brogren will leave the company to take up a CEO position in another company. Julie Waras Brogren joined Ascelia Pharma ...</description>
</item>
<item>
<title>Nomination Committee Appointed for AGM 2026 in Ascelia Pharma AB</title>
<link>https://6ix.com/company/ascelia-pharma-ab/news/nomination-committee-appointed-for-agm-2026-in-ascelia-pharma-ab-1</link>
<guid isPermaLink="true">https://6ix.com/company/ascelia-pharma-ab/news/nomination-committee-appointed-for-agm-2026-in-ascelia-pharma-ab-1</guid>
<pubDate>Mon, 22 Dec 2025 06:45:00 GMT</pubDate>
<description>MALMÖ, SE / ACCESS Newswire / December 22, 2025 / Ascelia Pharma AB (publ) (ticker:ACE)(STO:ACE) today announces that the Nomination Committee for the Annual General Meeting (AGM) on 4 May 2026 has been appointed In accordance with the instructions ...</description>
</item>
<item>
<title>Change in Number of Shares and Votes in Ascelia Pharma AB</title>
<link>https://6ix.com/company/ascelia-pharma-ab/news/change-in-number-of-shares-and-votes-in-ascelia-pharma-ab-1</link>
<guid isPermaLink="true">https://6ix.com/company/ascelia-pharma-ab/news/change-in-number-of-shares-and-votes-in-ascelia-pharma-ab-1</guid>
<pubDate>Fri, 28 Nov 2025 14:15:00 GMT</pubDate>
<description>MALMÖ, SE / ACCESS Newswire / November 28, 2025 / Ascelia Pharma (STO:ACE) During the month of November, the number of shares and votes in Ascelia Pharma AB have changed due to conversion of a total of 53,335 series C shares into a total of 53,335 ...</description>
</item>
<item>
<title>Ascelia Pharma Resolves on Conversion of Series C Shares into Ordinary Shares for Delivery to Participants in Incentive Program</title>
<link>https://6ix.com/company/ascelia-pharma-ab/news/ascelia-pharma-resolves-on-conversion-of-series-c-shares-into-ordinary-shares-for-delivery-to-participants-in-incentive-program-1</link>
<guid isPermaLink="true">https://6ix.com/company/ascelia-pharma-ab/news/ascelia-pharma-resolves-on-conversion-of-series-c-shares-into-ordinary-shares-for-delivery-to-participants-in-incentive-program-1</guid>
<pubDate>Wed, 19 Nov 2025 14:25:00 GMT</pubDate>
<description>MALMÖ, SE / ACCESS Newswire / November 19, 2025 / Ascelia Pharma (STO:ACE) - The Board of Directors of Ascelia Pharma AB ("Ascelia Pharma") has on 19 November 2025 resolved to convert 53,335 series C shares into ordinary shares for delivery of shares ...</description>
</item>
<item>
<title>Ascelia Pharma Announces FDA Acceptance of Orviglance New Drug Application for Review</title>
<link>https://6ix.com/company/ascelia-pharma-ab/news/ascelia-pharma-announces-fda-acceptance-of-orviglance-new-drug-application-for-review-1</link>
<guid isPermaLink="true">https://6ix.com/company/ascelia-pharma-ab/news/ascelia-pharma-announces-fda-acceptance-of-orviglance-new-drug-application-for-review-1</guid>
<pubDate>Sat, 15 Nov 2025 11:15:00 GMT</pubDate>
<description>MALMÖ, SE / ACCESS Newswire / November 15, 2025 / Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that the U.S. Food and Drug Administration (FDA) has accepted ...</description>
</item>
<item>
<title>Ascelia Pharma Files New Patent Application for Orviglance</title>
<link>https://6ix.com/company/ascelia-pharma-ab/news/ascelia-pharma-files-new-patent-application-for-orviglance-1</link>
<guid isPermaLink="true">https://6ix.com/company/ascelia-pharma-ab/news/ascelia-pharma-files-new-patent-application-for-orviglance-1</guid>
<pubDate>Mon, 10 Nov 2025 08:30:00 GMT</pubDate>
<description>MALMÖ, SE / ACCESS Newswire / November 10, 2025 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (ticker:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the filing of a new patent application ...</description>
</item>
<item>
<title>Ascelia Pharma Announces Management Changes to Support Future Growth</title>
<link>https://6ix.com/company/ascelia-pharma-ab/news/ascelia-pharma-announces-management-changes-to-support-future-growth-1</link>
<guid isPermaLink="true">https://6ix.com/company/ascelia-pharma-ab/news/ascelia-pharma-announces-management-changes-to-support-future-growth-1</guid>
<pubDate>Mon, 03 Nov 2025 10:15:00 GMT</pubDate>
<description>MALMÖ, SE / ACCESS Newswire / November 3, 2025 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (ticker:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced changes to its executive leadership ...</description>
</item>
<item>
<title>Ascelia Pharma Submits Orviglance New Drug Application to the U.S. Food and Drug Administration</title>
<link>https://6ix.com/company/ascelia-pharma-ab/news/ascelia-pharma-submits-orviglance-new-drug-application-to-the-us-food-and-drug-administration-1</link>
<guid isPermaLink="true">https://6ix.com/company/ascelia-pharma-ab/news/ascelia-pharma-submits-orviglance-new-drug-application-to-the-us-food-and-drug-administration-1</guid>
<pubDate>Wed, 03 Sep 2025 08:30:00 GMT</pubDate>
<description>MALMÖ, SE / ACCESS Newswire / September 3, 2025 / Ascelia Pharma AB (publ) (ticker:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that the New Drug Application (NDA) for Orviglance® has ...</description>
</item>
<item>
<title>Ascelia Pharma Updates Timeline for Submission of the Orviglance NDA</title>
<link>https://6ix.com/company/ascelia-pharma-ab/news/ascelia-pharma-updates-timeline-for-submission-of-the-orviglance-nda-1</link>
<guid isPermaLink="true">https://6ix.com/company/ascelia-pharma-ab/news/ascelia-pharma-updates-timeline-for-submission-of-the-orviglance-nda-1</guid>
<pubDate>Fri, 15 Aug 2025 16:40:00 GMT</pubDate>
<description>MALMÖ, SE / ACCESS Newswire / August 15, 2025 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (ticker:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today provided additional information regarding ...</description>
</item>
<item>
<title>Bulletin from the Annual General Meeting in Ascelia Pharma AB on 7 May 2025</title>
<link>https://6ix.com/company/ascelia-pharma-ab/news/bulletin-from-the-annual-general-meeting-in-ascelia-pharma-ab-on-7-may-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/ascelia-pharma-ab/news/bulletin-from-the-annual-general-meeting-in-ascelia-pharma-ab-on-7-may-2025-1</guid>
<pubDate>Wed, 07 May 2025 14:40:00 GMT</pubDate>
<description>MALMÖ, SE / ACCESS Newswire / May 7, 2025 / Ascelia Pharma (STO:ACE) - Today, on 7 May 2025, an annual general meeting was held in Ascelia Pharma AB. A summary of the adopted resolutions follows below. Resolution on adoption of accounts and allocation ...</description>
</item>
</channel>
</rss>